换一批A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
第一作者：
J P,Braybrooke
第一单位：
Department of Urology, Churchill Hospital, Oxford, United Kingdom.
作者：
医学主题词
成年人(Adult);老年人(Aged);抗肿瘤药(Antineoplastic Agents);癌, 肾细胞(Carcinoma, Renal Cell);无病生存(Disease-Free Survival);E选择素(E-Selectin);内皮生长因子类(Endothelial Growth Factors);女(雌)性(Female);成纤维细胞生长因子2(Fibroblast Growth Factor 2);人类(Humans);肾肿瘤(Kidney Neoplasms);淋巴因子(Lymphokines);男(雄)性(Male);中年人(Middle Aged);新生血管化, 病理性(Neovascularization, Pathologic);丙亚胺(Razoxane);受体, 细胞表面(Receptors, Cell Surface);受体, 尿激酶型纤溶酶原激活物(Receptors, Urokinase Plasminogen Activator);时间因素(Time Factors);拓扑异构酶II抑制剂(Topoisomerase II Inhibitors);治疗结果(Treatment Outcome);血管细胞黏附分子1(Vascular Cell Adhesion Molecule-1);血管内皮生长因子A(Vascular Endothelial Growth Factor A);血管内皮生长因子类(Vascular Endothelial Growth Factors);von Willebrand因子(von Willebrand Factor)
PMID
11156222
发布时间
2015-11-19
- 浏览29
Clinical cancer research
4697-704页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
